Mhairi Copland, BSc (Hons) MB ChB PhD FRCP FRCPath of the University of Glasgow, presents a press briefing of Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study at the 58th ASH Annual Meeting in San Diego, CA.
Decrease of Tyrosine Kinase Inhibitor in Patients with CML
